Ace inhibitor conversion chart
Searched over 200M research papers
Summary
4 papers analyzed
These studies suggest that certain soybean-derived peptides have ACE inhibitory effects, which could be beneficial for blood pressure control and glucose metabolism, and that advanced analytical methods can identify new ACE inhibitors using standard drugs like Captopril and Lisinopril as references.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
ACE Inhibitor Conversion Chart: Insights from Recent Research
Introduction to ACE Inhibitors
Angiotensin-converting enzyme (ACE) inhibitors are crucial in managing hypertension and related cardiovascular conditions. They work by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. This article synthesizes recent research on ACE inhibitors, focusing on their identification, metabolic effects, and potential applications.
Identification of Natural ACE Inhibitors
Soybean-Derived Peptides
Recent studies have identified natural ACE inhibitors from soybean protein isolates. Soybean protein hydrolysate (SPIH) prepared using Alcalase has shown significant ACE inhibitory activity. Specific peptides such as IY, YVVF, LVF, WMY, LVLL, and FF have been identified as potent inhibitors, with IY exhibiting the lowest IC50 value of 0.53 µM. These peptides maintain or even enhance their inhibitory activity after gastrointestinal digestion, making them promising candidates for functional foods aimed at blood pressure regulation.
Glycinin-Derived Peptides
Another study focused on glycinin, the major storage protein in soybeans, and its hydrolysates. The most potent ACE inhibitory peptide identified was Val-Leu-Ile-Val-Pro, with an IC50 value of 1.69 µM. This peptide acts as a competitive inhibitor and is resistant to gastrointestinal proteases, highlighting its potential for therapeutic use in functional foods.
Metabolic Effects of ACE Inhibitors
Impact on Insulin Resistance
ACE inhibitors are not only effective in controlling blood pressure but also have beneficial effects on metabolic control, particularly in insulin-resistant conditions. They enhance glucose uptake in skeletal muscle by increasing nitric oxide production through bradykinin B2 receptors and reducing the inhibitory effects of angiotensin II on glucose transport. Chronic administration of ACE inhibitors can upregulate insulin signaling pathways and increase the expression of GLUT-4 glucose transporters in skeletal muscle, thereby improving glucose disposal and overall metabolic control.
Screening and Optimization of ACE Inhibitors
HPLC-ESI-QqQ-MS Method
A novel method using high-performance liquid chromatography-electrospray ionization triple quadrupole mass spectrometry (HPLC-ESI-QqQ-MS) has been developed for the rapid and sensitive identification of ACE inhibitors. This method allows for precise measurement of angiotensin I conversion to angiotensin II, with a detection limit as low as 1.93 nM. Standard inhibitors like Captopril and Lisinopril have been validated using this method, with IC50 values of 3.969 µM and 0.852 µM, respectively. This technique is valuable for screening new ACE inhibitors with high precision and reproducibility.
Conclusion
The research highlights the potential of natural peptides derived from soybean proteins as effective ACE inhibitors. These findings, combined with advanced screening methods, pave the way for developing new therapeutic agents and functional foods aimed at managing hypertension and improving metabolic health. The dual benefits of ACE inhibitors in blood pressure control and metabolic regulation make them a critical area of ongoing research and application.
Sources and full results
Most relevant research papers on this topic
